Publications

Biosciences

831 results

Reversible host cell surface remodelling limits immune recognition and maximizes transmission of Plasmodium falciparum gametocytes.Ngotho P Press KD Peedell M Muasya W Omondi BR Otoboh SE Seydel KB Kapulu M Laufer M Taylor T Bousema T Marti M
bioRxiv, (2024). :

Bi-isotype immunoglobulins enhance antibody-mediated neutrophil activity against Plasmodium falciparum parasites.Ogwang R Murugu L Nkumama IN Nyamako L Kai O Mwai K Murungi L Idro R Bejon P Tuju J Kinyanjui SM Osier FHA
Front Immunol, (2024). 15:1360220

Editorial: Malaria molecular epidemiology current situation in Africa.Tandoh KZ Duah-Quashie NO Raman J Ochola-Oyier LI
Front Epidemiol, (2024). 4:1400612

Feasibility, safety, and impact of the RTS,S/AS01(E) malaria vaccine when implemented through national immunisation programmes: evaluation of cluster-randomised introduction of the vaccine in Ghana, Kenya, and Malawi.Asante KP Mathanga DP Milligan P Akech S Oduro A Mwapasa V Moore KA Kwambai TK Hamel MJ Gyan T Westercamp N Kapito-Tembo A Njuguna P Ansong D Kariuki S Mvalo T Snell P Schellenberg D Welega P Otieno L Chimala A Afari EA Bejon P Maleta K Agbenyega T Snow RW Zulu M Chinkhumba J Samuels AM Malaria Vaccine Programme Evaluation Partners
Lancet, (2024). 403:1660-1670

Age-dependent acquisition of IgG antibodies to Shigella serotypes-a retrospective analysis of seroprevalence in Kenyan children with implications for infant vaccination.Kapulu MC Muthumbi E Otieno E Rossi O Ferruzzi P Necchi F Acquaviva A Martin LB Orindi B Mwai K Kibet H Mwanzu A Bigogo GM Verani JR Mbae C Nyundo C Agoti CN Nakakana UN Conti V Bejon P Kariuki S Scott JAG Micoli F Podda A
Front Immunol, (2024). 15:1340425

Fourth Controlled Human Infection Model (CHIM) meeting - CHIMs in endemic countries, May 22-23, 2023.Kapulu M Manda-Taylor L Balasingam S Means G Ayiro Malungu M Bejon P Chi PC Chiu C Church EC Correa-Oliveira R Day N Durbin A Egesa M Emerson C Jambo K Mathur R Metzger W Mumba N Nazziwa W Olotu A Rodgers J Sinyiza F Talaat K Kamerling I Weller C Baay M Neels P
Biologicals, (2024). 85:101747

Fourth Controlled Human Infection Model (CHIM) meeting, CHIM regulatory issues, May 24, 2023.Cavaleri M Kaslow D Boateng E Chen WH Chiu C Choy RKM Correa-Oliveira R Durbin A Egesa M Gibani M Kapulu M Katindi M Olotu A Pongsuwan P Simuyandi M Speder B Talaat KR Weller C Wills B Baay M Balasingam S Olesen OF Neels P
Biologicals, (2024). 85:101745

Safety and efficacy of malaria vaccine candidate R21/Matrix-M in African children: a multicentre, double-blind, randomised, phase 3 trial.Datoo MS Dicko A Tinto H Ouedraogo JB Hamaluba M Olotu A Beaumont E Ramos Lopez F Natama HM Weston S Chemba M Compaore YD Issiaka D Salou D Some AM Omenda S Lawrie A Bejon P Rao H Chandramohan D Roberts R Bharati S Stockdale L Gairola S Greenwood BM Ewer KJ Bradley J Kulkarni PS Shaligram U Hill AVS R1/Matrix-M Phase 3 Trial Group
Lancet, (2024). 403:533-544

Distinct transcriptomic signatures define febrile malaria depending on initial infective states, asymptomatic or uninfected.Kimenyi KM Akinyi MY Mwikali K Gilmore T Mwangi S Omer E Gichuki B Wambua J Njunge J Obiero G Bejon P Langhorne J Abdi A Ochola-Oyier LI
BMC Infect Dis, (2024). 24:140

Exposure to common infections may shape basal immunity and potentially HIV-1 acquisition amongst a high-risk population in Coastal Kenya.Fwambah L Andisi C Streatfield C Bromell R Hare J Esbjornsson J Ndung'u T Sanders EJ Hassan AS Nduati E
Front Immunol, (2024). 14:1283559

A metabolic perspective of the neutrophil life cycle: new avenues in immunometabolism.Thind MK Uhlig HH Glogauer M Palaniyar N Bourdon C Gwela A Lancioni CL Berkley JA Bandsma RHJ Farooqui A
Front Immunol, (2024). 14:1334205

Sugar and blood: the nutritional priorities of the dengue vector, Aedes aegypti.Tenywa FC Musa JJ Musiba RM Swai JK Mpelepele AB Okumu FO Maia MF
Parasit Vectors, (2024). 17:26

Targeted amplicon deep sequencing of ama1 and mdr1 to track within-host P. falciparum diversity throughout treatment in a clinical drug trial.Wamae K Ndwiga L Kharabora O Kimenyi K Osoti V de Laurent Z Wambua J Musyoki J Ngetsa C Kalume P Mwambingu G Hamaluba M van der Pluijm R Dondorp AM Bailey J Juliano J Bejon P Ochola-Oyier L
Wellcome Open Res, (2024). 7:95

Safety and immunogenicity of varied doses of R21/Matrix-M vaccine at three years follow-up: A phase 1b age de-escalation, dose-escalation trial in adults, children, and infants in Kilifi-Kenya.Sang S Datoo MS Otieno E Muiruri C Bellamy D Gathuri E Ngoto O Musembi J Provstgaard-Morys S Stockdale L Aboagye J Woods D Lawrie A Roberts R Keter K Kimani D Ndungu F Kapulu M Njau I Orindi B Ewer KJ Hill AVS Bejon P Hamaluba M
Wellcome Open Res, (2023). 8:450

Safety and immunogenicity of ChAdOx1 nCoV-19 (AZD1222) vaccine in adults in Kenya: a phase 1/2 single-blind, randomised controlled trial.Hamaluba M Sang S Orindi B Njau I Karanja H Kamau N Gitonga JN Mugo D Wright D Nyagwange J Kutima B Omuoyo D Mwatasa M Ngetsa C Agoti C Cheruiyot S Nyaguara A Munene M Mturi N Oloo E Ochola-Oyier L Mumba N Mauncho C Namayi R Davies A Tsofa B Nduati EW Aliyan N Kasera K Etyang A Boyd A Hill A Gilbert S Douglas A Pollard A Bejon P Lambe T Warimwe G COVVaccine Trial Group
Wellcome Open Res, (2023). 8:182

Low frequency of Plasmodium falciparum hrp2/3 deletions from symptomatic infections at a primary healthcare facility in Kilifi, Kenya.Okanda D Ndwiga L Osoti V Achieng N Wambua J Ngetsa C Lubell-Doughtie P Shankar A Bejon P Ochola-Oyier LI
Front Epidemiol, (2023). 3:1083114

Where do those data go? Reuse of screening results from clinical trials to estimate population prevalence of HBV infection in adults in Kilifi, Kenya.Downs LO Campbell C Abouyannis M Otiende M Kapulu M Obiero CW Hamaluba M Ngetsa C Andersson MI Githinji G Warimwe G Baisley K Scott JAG Matthews PC Etyang A
J Virus Erad, (2023). 9:100355

Quick links